NCT06237803 European Myeloma Network (EMN) Sample Project
| NCT ID | NCT06237803 |
| Status | Recruiting |
| Phase | — |
| Sponsor | European Myeloma Network B.V. |
| Condition | Multiple Myeloma |
| Study Type | OBSERVATIONAL |
| Enrollment | 6,000 participants |
| Start Date | 2022-12-21 |
| Primary Completion | 2037-12 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 6,000 participants in total. It began in 2022-12-21 with a primary completion date of 2037-12.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This is an observational, non-interventional, multicenter study for the prospective collection, storage and analysis of patients' biological samples. This study establishes a common international infrastructure useful to collect standard clinical variables at baseline and during treatment and to uniformly collect and store biological samples
Eligibility Criteria
Inclusion Criteria: * Subjects with MGUS, smouldering Multiple Myeloma (SMM) , MM (Multiple Myeloma) (+/- EMD), plasma cell leukemia (PCL) (+/- EMD) * Subjects are ≥ 18 years old. * Subjects have provided written informed consent in accordance with federal, local, and institutional guidelines prior to initiation of any project-specific activities or procedures. 1. Subjects do not have kind of condition that, in the opinion of the Investigators, may compromise the ability of the subjects to give written informed consent and 2. subjects are, in the investigator's opinion, willing and able to comply with the protocol requirements. Exclusion Criteria: * Previous treatment with anti-myeloma therapy (excluding one course of therapy in patients in which urgent therapy is deemed necessary according to physician's discretion, e.g. myeloma-related complications resistant to supportive care). * Subjects have had prior unforeseen (serious) adverse reactions to blood donation including, but not limited to fainting, angina, severe bruising, allergic reactions, or any other adverse events. * Any psychological, familial, sociological and geographical condition potentially hampering compliance with the protocol and follow-up schedule.
Contact & Investigator
Frequently Asked Questions
Who can join the NCT06237803 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Multiple Myeloma. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06237803 currently recruiting?
Yes, NCT06237803 is actively recruiting participants. Contact the research team at chiara.delpietro@emn.org for enrollment information.
Where is the NCT06237803 trial being conducted?
This trial is being conducted at Melbourne, Australia, Linz, Austria, Vienna, Austria, Leuven, Belgium and 11 additional locations.
Who is sponsoring the NCT06237803 clinical trial?
NCT06237803 is sponsored by European Myeloma Network B.V.. The trial plans to enroll 6,000 participants.